The Richter Gedeon Nyr has announced a massive downsizing.

The pharmaceutical company Richter Gedeon Nyrt., one of Hungary's largest drug manufacturers, has announced plans to reduce its workforce by more than thirty employees within a period of thirty days. This decision marks a significant step in the company’s restructuring efforts, as the number of layoffs now meets the threshold for a group-level reduction in staff size. The company informed the Budapest Capital Government Office about this development on Monday, according to reports from the Hungarian News Agency (MTI). Currently, over six thousand employees work across the company’s various facilities.

According to the company’s statement, the planned reduction primarily affects areas related to drug production, particularly the manufacturing of active pharmaceutical ingredients. These operations play a crucial role in the overall business strategy of Richter, which operates across several European Union countries. The company emphasized that maintaining the competitiveness of these activities presents a serious challenge for pharmaceutical companies operating within the EU, including Richter itself.

This announcement comes amid ongoing financial pressures faced by the company. Earlier this year, in April, it was reported that Richter had decided to defer dividend payments to shareholders associated with the MCC (Magyar Csillagászati és Földtani Intézet) until the situation regarding foundation-funded universities stabilizes. Additionally, last autumn, the company reportedly transferred three billion forints to address issues arising from the strong Hungarian forint, which had impacted its financial standing.

Richter’s decision to implement a workforce reduction reflects broader challenges facing the pharmaceutical industry in Europe. The sector has been under pressure due to fluctuating currency values, rising production costs, and increasing competition among international players. For Richter, maintaining a competitive edge in the production of active pharmaceutical ingredients—key components used in drug manufacturing—is essential but increasingly difficult given current economic conditions.

The company’s spokesperson highlighted that while the reduction in workforce will affect certain departments, the overall strategic direction remains focused on sustaining long-term growth and ensuring operational efficiency. The changes are part of a larger effort to adapt to evolving market demands and regulatory requirements both domestically and internationally.

Industry analysts suggest that such measures are becoming more common as companies seek to streamline operations and reduce overheads. However, the impact on local employment and the broader economy remains a concern for policymakers and labor representatives. The Hungarian government has previously expressed interest in supporting domestic industries, especially those deemed critical to national health and security.

Looking ahead, Richter is expected to provide further updates on the implementation of its restructuring plan. The company has not yet specified whether additional reductions might follow in the coming months, nor has it outlined how affected employees will be supported during the transition. As the pharmaceutical landscape continues to evolve, the decisions made by companies like Richter will have lasting implications for both their internal operations and the wider economic environment.